Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (331-340 of 372) with videos related to

Pageof 38
Sort By:
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Science (New York, N.Y.)|April 6, 2013
Influence of HLA-C expression level on HIV controlRichard Apps, Ying Qi, Jonathan M Carlson, et al.
Vaccines|October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient TransfectionAgnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Eclinicalmedicine|August 3, 2023
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyGuy de Bruyn, Joyce Wang, Annie Purvis, et al.
Virus Evolution|June 24, 2026
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animalsAnise N Happi, Olusola A Ogunsanya, Ayotunde E Sijuwola, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Cell Reports. Medicine|April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaquesJingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
Pageof 38

Showing results (331-340 of 372) with videos related to

Sort By:
Pageof 38
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Science (New York, N.Y.)|April 6, 2013
Influence of HLA-C expression level on HIV controlRichard Apps, Ying Qi, Jonathan M Carlson, et al.
Vaccines|October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient TransfectionAgnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Eclinicalmedicine|August 3, 2023
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyGuy de Bruyn, Joyce Wang, Annie Purvis, et al.
Virus Evolution|June 24, 2026
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animalsAnise N Happi, Olusola A Ogunsanya, Ayotunde E Sijuwola, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Cell Reports. Medicine|April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaquesJingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
Pageof 38